183 related articles for article (PubMed ID: 34559006)
1. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Messiou C; Porta N; Sharma B; Levine D; Koh DM; Boyd K; Pawlyn C; Riddell A; Downey K; Croft J; Morgan V; Stern S; Cheung B; Kyriakou C; Kaczmarek P; Winfield J; Blackledge M; Oyen WJG; Kaiser MF
Radiol Imaging Cancer; 2021 Sep; 3(5):e210048. PubMed ID: 34559006
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
3. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial.
Mesguich C; Hulin C; Latrabe V; Asselineau J; Bordenave L; Perez P; Hindie E; Marit G
JMIR Res Protoc; 2020 Sep; 9(9):e17850. PubMed ID: 32909953
[TBL] [Abstract][Full Text] [Related]
4. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of
Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
[TBL] [Abstract][Full Text] [Related]
7. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma.
Gómez León N; Aguado Bueno B; Herreros Pérez M; León Ramírez LF; Alegre A; Colletti PM; Rubello D; Carreras JL; Delgado Bolton RC
Clin Nucl Med; 2021 Apr; 46(4):310-322. PubMed ID: 33534256
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Whole-Body DWI and
Chen J; Li C; Tian Y; Xiao Q; Deng M; Hu H; Wen B; He Y
AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755
[No Abstract] [Full Text] [Related]
9. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.
De Paepe KN; Van Keerberghen CA; Agazzi GM; De Keyzer F; Gheysens O; Bechter O; Wolter P; Dierickx D; Janssens A; Verhoef G; Oyen R; Koole M; Vandecaveye V
Radiol Imaging Cancer; 2021 Mar; 3(2):e200061. PubMed ID: 33817648
[TBL] [Abstract][Full Text] [Related]
11. Optimization of whole-body 2-[
Burns R; Mulé S; Blanc-Durand P; Tofighi M; Belhadj K; Zerbib P; Le Bras F; Baranes L; Haioun C; Itti E; Luciani A
Eur Radiol; 2022 May; 32(5):3085-3096. PubMed ID: 34842956
[TBL] [Abstract][Full Text] [Related]
12. Dual-tracer PET/CT scan after injection of combined [
Withofs N; Beguin Y; Cousin F; Tancredi T; Simoni P; Alvarez-Miezentseva V; De Prijck B; Hafraoui K; Bonnet C; Baron F; Hustinx R; Caers J
Hematol Oncol; 2019 Apr; 37(2):193-201. PubMed ID: 30821017
[TBL] [Abstract][Full Text] [Related]
13.
Wardak M; Sonni I; Fan AP; Minamimoto R; Jamali M; Hatami N; Zaharchuk G; Fischbein N; Nagpal S; Li G; Koglin N; Berndt M; Bullich S; Stephens AW; Dinkelborg LM; Abel T; Manning HC; Rosenberg J; Chin FT; Gambhir SS; Mittra ES
Radiology; 2022 Jun; 303(3):620-631. PubMed ID: 35191738
[TBL] [Abstract][Full Text] [Related]
14. (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.
Lin C; Ho CL; Ng SH; Wang PN; Huang Y; Lin YC; Tang TC; Tsai SF; Rahmouni A; Yen TC
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):41-9. PubMed ID: 24129710
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
16. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
17. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
18. Whole-body MRI versus an [
Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]